CORDIS
EU research results

CORDIS

English EN
Non-coding RNAs in neurogenic and neuropathic pain mechanisms and their application for risk assessment, patient stratification and personalised pain medicine

Non-coding RNAs in neurogenic and neuropathic pain mechanisms and their application for risk assessment, patient stratification and personalised pain medicine

Objective

Neuro-immune alterations in the peripheral and central nervous system play a role in the pathophysiology of chronic pain, and non-coding RNAs (ncRNAs) regulate both immune and neuronal processes. Therefore, ncRNAPain proposes that ncRNAs are critically important master switches for chronic pain.

ncRNAPain represents a multidisciplinary consortium of clinical partners, molecular and systems-level neuroscientists, bioinformatics and ncRNA experts. In order to gain knowledge on the mechanisms of chronic pain, ncRNAPain will investigate ncRNAs specifically in neurogenic and neuropathic pain, including headache.

ncRNAPain will provide novel understanding of ncRNA regulation of processes modulating nociception and endogenous analgesia and of the importance of ncRNAs in circuitries and cognitive, emotional and behavioural components of pain. ncRNAPain will reveal insights into the concerted function of ncRNAs in the control of macromolecular complexes in neurons, glia and immune cells and signals used for neuroimmune communication in the pain pathway. Based on these findings, ncRNAPain will identify and validate specific ncRNAs as new druggable molecular targets for pain prevention and relief. ncRNAPain will identify pain predisposing ncRNA expression patterns and polymorphisms in ncRNAS and/or their binding sites as biomarkers for pain and inter-individual variations in the response to painful stimuli and analgesic drugs. ncRNA-based diagnostic tools will be developed and provided to enable better patient stratification, improved mechanism-based treatment and targeted prevention strategies for high risk individuals.

ncRNAPain will provide novel understanding of the induction and maintenance of chronic pain and is committed to translate pre-clinical and clinical results and developments into clinical applications for the benefit of the patients, to improve the patients’ quality of life and reduce the societal burden of chronic pain across Europe.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

MEDIZINISCHE UNIVERSITAT INNSBRUCK

Address

Christoph Probst Platz 1
6020 Innsbruck

Austria

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 699 160

Administrative Contact

Wolfram Rieneck (Dr.)

Participants (11)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITE VICTOR SEGALEN BORDEAUX II

France

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Germany

EU Contribution

€ 581 140

UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ

Germany

EU Contribution

€ 398 826

EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH

Germany

EU Contribution

€ 428 100

UNIVERSITATSKLINIKUM HEIDELBERG

Germany

EU Contribution

€ 392 640

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 400 920

Masarykova univerzita

Czechia

EU Contribution

€ 310 933

UNIVERSITE DE BORDEAUX

France

EU Contribution

€ 362 640

EXIQON AS

Denmark

EU Contribution

€ 467 916

THE HEBREW UNIVERSITY OF JERUSALEM

Israel

EU Contribution

€ 525 960

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

EU Contribution

€ 420 600

Project information

Grant agreement ID: 602133

Status

Closed project

  • Start date

    1 October 2013

  • End date

    30 September 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 805 149,60

  • EU contribution

    € 5 988 835

Coordinated by:

MEDIZINISCHE UNIVERSITAT INNSBRUCK

Austria